ReviewHuman vaccines & immunotherapeutics2019
The development of a staphylococcus aureus four antigen vaccine for use prior to elective orthopedic surgery.
Review in Human vaccines & immunotherapeutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 22 citations in OpenAlex.
- Efficacy of a 4-Antigen Staphylococcus aureus Vaccine in Spinal Surgery: The STaphylococcus aureus suRgical Inpatient Vaccine Efficacy (STRIVE) Randomized Clinical Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Trial
- Dual-mode ClfA-targeting DARPin biologics protect against diverse methicillin-resistantbioRxiv : the preprint server for biology · 2026Article
- Diabetes mellitus is an independent risk factor for surgical site infection after orthopedic Class I incision surgery: a retrospective cohort study.Frontiers in surgery · 2026Article
- Taming Superbugs: Current Progress and Challenges in Combating ESKAPE Pathogens.Pathogens (Basel, Switzerland) · 2025Review
- Design of a multi-epitope vaccine against Staphylococcus Aureus lukotoxin ED using in silico approaches.Scientific reports · 2025Article
- Conserved moonlighting protein pyruvate dehydrogenase induces robust protection againstProceedings of the National Academy of Sciences of the United States of America · 2024Article
- Reverse development of vaccines against antimicrobial-resistant pathogens.NPJ vaccines · 2024Review
- Non-protective immune imprint underlies failure of Staphylococcus aureus IsdB vaccine.Cell host & microbe · 2022Article
- Integrating complex host-pathogen immune environments into S. aureus vaccine studies.Cell chemical biology · 2022Review
- Review
- Bacterial-viral interactions: a factor that facilitates transmission heterogeneities.FEMS microbes · 2022Article
- Evaluation of the metagenomic next-generation sequencing performance in pathogenic detection in patients with spinal infection.Frontiers in cellular and infection microbiology · 2022Article
- Evasion of Immunological Memory byFrontiers in immunology · 2021Review
- T Cell Immunity and the Quest for Protective Vaccines againstMicroorganisms · 2020Review
- Persistence of Immune Responses Through 36 Months in Healthy Adults After Vaccination With a NovelOpen forum infectious diseases · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Staphylococcus aureus (S. aureus) is a challenging bacterial pathogen which can cause a range of diseases, from mild skin infections, to more serious and invasive disease including deep or organ space surgical site infections, life-threatening bacteremia, and sepsis. S. aureus rapidly develops resistance to antibiotic treatments. Despite current infection control measures, the burden of disease remains high. The most advanced vaccine in clinical development is a 4 antigen S. aureus vaccine (SA4Ag) candidate that is being evaluated in a phase 2b/3 efficacy study in patients undergoing elective spinal fusion surgery (STaphylococcus aureus suRgical Inpatient Vaccine Efficacy [STRIVE]). SA4Ag has been shown in early phase clinical trials to be generally safe and well tolerated, and to induce high levels of bactericidal antibodies in healthy adults. In this review we discuss the design of SA4Ag, as well as the proposed clinical development plan supporting licensure of SA4Ag for the prevention of invasive disease caused by S. aureus in elective orthopedic surgical populations. We also explore the rationale for the generalizability of the results of the STRIVE efficacy study (patients undergoing elective open posterior multilevel instrumented spinal fusion surgery) to a broad elective orthopedic surgery population due to the common pathophysiology of invasive S. aureus disease and commonalties of patient and procedural risk factors for developing postoperative S. aureus surgical site infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.